Danish drugmaker Zealand Pharma has entered a collaboration with Generate Biomedicines to develop obesity treatments using the latter’s generative AI protein design platform. The deal includes a $30 million upfront payment, up to $35 million in preclinical milestone payments, and total potential payments including tiered royalties reaching approximately $1.2 billion. Generate Biomedicines, listed on Nasdaq since February 2026, saw its shares rise about 5% in after-hours trading following the announcement. Zealand will assume responsibility for clinical development and worldwide commercialization of any resulting therapeutics.
Source: Read the original article
Disclaimer: this content is for information purposes only and is not financial advice. Cryptocurrencies are highly volatile: you may lose all of your capital. Always do your own research. Legal notice
